Logo

Galapagos Extends by $1M siRNA-Based Target-Validation Deal With Cystic Fibrosis Foundation

Nov 22, 2006
NEW YORK (GenomeWeb News) — Galapagos has extended by 15 months and €800,000 ($1 million) a two-year agreement with Cystic Fibrosis Foundation Therapeutics to use its siRNA and cDNA collections to develop new treatments for cystic fibrosis, the company said today.
 
Galapagos said its BioFocus DPI division is using its SilenceSelect adenoviral library to design assays that can identify and validate potential targets that could be the “basis for the development of new medicines.”   
 
Galapagos signed the original two-year, €1.3-million research agreement with CFFT, a drug development affiliate of the Cystic Fibrosis Foundation, in April 2005.

Filed under

Gene Editing, Gene Silencing, & CRISPR
RNAi
Breaking News
The Scan

Harvard Team Report One-Time Base Editing Treatment for Motor Neuron Disease in Mice

A base-editing approach restored SMN levels and improved motor function in a mouse model of spinal muscular atrophy, a new Science paper reports.

International Team Examines History of North American Horses

Genetic and other analyses presented in Science find that horses spread to the northern Rockies and Great Plains by the first half of the 17th century.

New Study Examines Genetic Dominance Within UK Biobank

Researchers analyze instances of genetic dominance within UK Biobank data, as they report in Science.

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.